Superluminal Medicines, a Boston, MA-based generative biology and chemistry company, raised $33M in Seed funding.
The round was led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels.
The company intends to use the funds to progress its pipeline of small molecule drug discovery programs initially focused on high-value G protein-coupled receptor (GPCR) targets.
Led by CEO Cony D’Cruz, Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline. Its platform creates candidate-ready compounds with speed using a comprehensive combination of biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is empowered by a pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, the company’s proprietary pipeline validates its platform with initial programs focused on GPCR targets.
The leadership includes: Cony D’Cruz, Co-Founder & CEO; Ajay Yekkirala, Co-Founder & SVP, Head of Discovery; Yang-Ming Zhu, SVP, Head of Engineering; Yamina A. Berchiche, Senior Director, Biology; Marek Orzechowski, Director, Computational Chemistry; and Murco Ringnalda, SVP, Head of Operations.
The board of directors includes: Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management; Dylan Morris, Managing Director at Insight Partners; and Cony D’Cruz, Chief Executive Officer of Superluminal Medicines.
FinSMEs
04/09/2023